Kardigan, Inc. Common Stock (KARD) Stock
Key stats
- Market cap
- $1.47B
- Price / Earnings ratio
- -7.4x
- EPS (TTM)
- -$23.63
- Volume
- Loading
- 52-week high
- $27.00
- 52-week low
- $12.23
Source: third-party data provider, as of November 13, 2026
Compare with KARD
Recent news

Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
KARD

Kardigan to Present at Two September Investor Conferences
Kardigan to Present at Two September Investor Conferences
KARD

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
KARD

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
KARD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 56.86
- MACD 12/26/9
- 0.08
- EMA 9 of MACD
- -0.27
- MACD histogram
- 0.35
- SMA 50
- $15.44
- Price above SMA 50
- EMA 50
- $15.65
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
KARD

Kardigan to Present at Two September Investor Conferences
Kardigan to Present at Two September Investor Conferences
KARD

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
KARD

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
KARD

Kardigan rises in Nasdaq debut after upsized $400 million IPO
Kardigan rises in Nasdaq debut after upsized $400 million IPO
KARD

Kardigan Announces Pricing of Upsized Initial Public Offering
Kardigan Announces Pricing of Upsized Initial Public Offering
KARD

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
KARD

Cardiovascular drug developer Kardigan files for US IPO
Cardiovascular drug developer Kardigan files for US IPO
KARD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Kardigan, Inc. Common Stock
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. The company leverages deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale. Its management team includes leaders from MyoKardia, Inc. ("MyoKardia") with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA | Co-Founder, President, CEO & Chairman | 1973 |
| Ms. Brianne Puglisi | Chief Financial Officer | 1987 |
| Dr. Jay Edelberg M.D., Ph.D. | Co-founder & Chief Medical Officer | 1964 |
| Dr. Bob McDowell Ph.D. | Co-founder & Scientific Advisor | — |
| Dr. Leslie A. Leinwand Ph.D. | Co-Founder | — |
| Dr. Elizabeth McNally M.D., Ph.D. | Co-Founder | 1961 |
| Mr. Donald Mackenzie Ph.D. | Chief Technical Operations Officer | — |
| Mr. Clayton Robertson | Vice President of Investor Relations | — |
| Mr. John B. Moriarty Jr., ESQ., J.D. | Chief Legal Officer & Corporate Secretary | 1968 |
| Ms. Emily Faucette | Chief Communications Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.86
- MACD 12/26/9
- 0.08
- EMA 9 of MACD
- -0.27
- MACD histogram
- 0.35
- SMA 50
- $15.44
- Price above SMA 50
- EMA 50
- $15.65
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $25.00
- Average
- $41.20
- High
- $50.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.4 | -13.6 | +1.0 | -24.7 | -0.8 | +10.3 |



